Aesthetics Has a Perimenopause Gap-- New Survey From Revance Uncovers What Women Are Seeking
Seventy-four percent of women say menopause increased their interest in aesthetic treatments, fueling demand for providers who understand hormonal aging and can integrate aesthetics, wellness, and regenerative care.
NASHVILLE, Tenn., Oct. 27, 2026 /PRNewswire/ -- Revance, a global aesthetics, regenerative and consumer skincare company, today announced new survey findings conducted with NewBeauty's BeautyEngine™, revealing that menopause is increasingly influencing how women approach aesthetic care. As hormonal changes reshape skin quality, treatment goals, and wellness priorities, women are seeking providers who can deliver a more informed, integrated approach to healthy aging. Survey findings suggest this shift is creating a new category of menopause-informed aesthetic care.
The survey of 1,279 women ages 23 to 781 found that 74% reported becoming more interested in aesthetic treatments after entering perimenopause or menopause, while 68% said they find the idea of receiving aesthetic and hormone care within the same practice appealing. At the same time, 85% said it is important that their aesthetic healthcare provider understands the unique impacts of perimenopause and menopause.1
In response to these evolving needs, Revance is taking a lead in advancing menopause-informed aesthetic care, deepening its commitment through dedicated provider education and initiatives designed to build understanding of how the biological changes associated with perimenopause and menopause can impact aesthetic care. Together with its portfolio of medical aesthetics and regenerative treatments, including DAXXIFY®, the Teoxane RHA® Collection, and SkinPen®, Revance is equipping providers with the education and tools to better address patients' evolving needs, deliver outcomes aligned with their changing biology, and build lasting relationships rooted in trust and expertise.
"For many, aesthetics and menopause care have largely existed in separate conversations, despite the significant impact hormonal changes can have on skin health, treatment expectations, and overall confidence," said Adelle Walker, Chief Marketing Officer, Aesthetics at Revance. "What we're seeing now is the emergence of a patient who expects providers to understand the full spectrum of aging. This shift represents an important opportunity for the aesthetics industry to better serve women through education, personalization, and treatment strategies that reflect their changing needs."
Key Findings:
Among women in perimenopause, menopause, or post-menopause:
- 63.6% said it is very important that their aesthetic healthcare provider understands perimenopause and menopause, while 85% said this expertise is important overall.1
- 39% had already shifted toward regenerative aesthetic options since entering peri/menopause.1
- 55% expressed interest in peptide injections, while 61% said they would be more likely to receive an aesthetic treatment that features peptides.1
The research also revealed that many women experienced noticeable changes in how their skin and aesthetic treatments respond during menopause. Loss of firmness emerged as the leading concern, cited by 74% of respondents, followed by fine lines and wrinkles (66%), changes in the jawline and neck (47%), and facial volume loss (46%).1
Additionally, among women who had previously received aesthetic treatments, more than one-third reported that treatments work less effectively than they did before entering perimenopause or menopause.1 Nearly half reported that results do not last as long as they once did.1
"In clinical practice, we frequently see patients notice changes in skin quality, elasticity, hydration, and treatment durability during perimenopause and menopause," said Dr. Ellen Marmur, board certified dermatologist. "These changes often require a more individualized approach to treatment planning. Understanding the physiologic effects of hormonal shifts can help providers set expectations, adapt treatment strategies, and deliver outcomes that align with patients' evolving goals."
Providers can learn more about Revance's approach and educational initiatives around menopause at the 2026 ASDS Annual Meeting by visiting Revance at Booth 211 or Revance Medical Affairs at Booth 311.
About Revance
Revance is a global company developing, producing, and distributing industry-leading, differentiated products across aesthetics, skincare, and therapeutics. Revance drives innovation beyond convention to offer treatment options for individuals across generations. The company's vision is to redefine excellence in aesthetics, skincare, and therapeutics through science-powered innovation, with an unwavering commitment to its providers, patients, and consumers. Revance's award-winning products are the result of robust research and development, a cornerstone for the company, driven by renowned scientists. For more information about Revance, please visit us at www.revance.com.
Media Contact:
EvolveMKD
[email protected]
- BeautyEngine Advanced Market Research Study, May 2026
The Teoxane RHA® Collection
The Teoxane RHA® Collection includes hyaluronic acid (HA) fillers with lidocaine and mepivacaine. Revance will only distribute the Teoxane RHA® Collection with mepivacaine, thus may refer to the products without the use of "Mepi" in the product name. The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine, and mepivacaine has shown no significant impact on gel properties, including rheology and degradation profile.
Approved Uses of RHA® Collection of Fillers by Teoxane
The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4 with lidocaine and RHA Redensity® Mepi, RHA Redensity® Eye, RHA® 2 Mepi, RHA® 3 Mepi and RHA® Dynamic Volume, with mepivacaine.
RHA Redensity® and RHA Redensity® Mepi are for the correction of moderate to severe dynamic perioral rhytids. RHA Redensity® Eye is for the correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults aged 22 years or older. RHA® 2, RHA® 2 Mepi and RHA® 4 are for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs), in adults 22 or older. RHA® 3 and RHA® 3 Mepi are for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs), and to augment lip fullness in adults 22 or older. RHA® Dynamic Volume is for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs), and for cheek augmentation and/or correction of age-related midface contour deficiencies in adults 22 or older.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any RHA® injectable gel formulation?
Do not receive if you have a history of multiple severe allergies or severe allergic reactions; if you are allergic to lidocaine or mepivacaine or gram-positive bacterial proteins; or if you have a bleeding disorder.
What precautions should I discuss with my doctor?
- Tell your doctor if you are pregnant or breastfeeding as the safety of these products for use during pregnancy or while breastfeeding has not been studied
- Tell your doctor if you have a history of excessive scarring, keloid formations or pigmentation disorders, as use of these products may result in additional scars or changes in pigmentation
- Tell your doctor if you are planning laser treatments or a chemical peel, as there is a possible risk of inflammation at the treatment site if these procedures are performed after treatment
- Tell your doctor if you are on immunosuppressive therapy used to decrease your immune response, as use of these products may result in an increased risk of infection
- Tell your doctor if you are using medications that can prolong bleeding, such as aspirin, ibuprofen, or other blood thinners, as this may increase bruising or bleeding at the injection site
- The safety and effectiveness of RHA® fillers in areas other than those indicated have not been established in U.S. clinical studies
- Patients who experience skin injury near the site of injection with this product may be at a higher risk for side effects
- Minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment
What are possible side effects?
The most commonly reported side effects included injection site redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching.
One of the risks with using these products is unintentional injection into a blood vessel, and while rare, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring.
Delayed-onset inflammation and granulomas (red raised lumps) near the site of dermal filler injections are known side effects associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to being treated or resolved on its own. Granulomas may appear weeks or months after injection and may require medical intervention.
As with all skin injection procedures, there is a risk of infection and recurrence of herpetic eruptions.
To report an adverse event with any RHA® product to Revance, please visit Safety.Revance.com or call at 1 (877) 373-8669.
Please visit RHACollection.com or talk to your doctor for more information.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
Available by prescription only.
RHA-00220
IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection
DAXXIFY® may cause serious side effects that can be life threatening. Get medical help right awayif you have any of these problems any time (hours to weeks) after injection of DAXXIFY®:
- Problems swallowing, speaking, or breathing due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
Do not receive DAXXIFY® if you are allergic to any of the ingredients in DAXXIFY® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such asrimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), incobotulinumtoxinA (XEOMIN®) or prabotulinumtoxinA-xvfs (JEUVEAU®); or have a skin infection at the planned injection site.
DAXXIFY® dosing units are not the same as, or comparable to, any other botulinum toxin product.
Tell your healthcare provider about all your medical conditions, including any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Using DAXXIFY® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received DAXXIFY® in the past.
Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as BOTOX®, BOTOX® Cosmetic, MYOBLOC®, DYSPORT®, XEOMIN®, or JEUVEAU®). DAXXIFY® may cause serious side effects, including allergic reactions (such as itching, rash, redness, swelling, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get medical help right away if you experience a serious side effect. No serious adverse events of distant spread of toxin effect associated with dermatologic use of DAXXIFY® have been reported in clinical studies at the dose of 40 Units for glabellar lines. The most common side effects of DAXXIFY® include headache, eyelid drooping, and loss of ability to move the muscles in your face.
These are not all the possible side effects of DAXXIFY®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor.
To report side effects associated with DAXXIFY®, please call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
APPROVED USE
DAXXIFY® is a prescription medicine that is injected into muscles and used in adults to temporarily improve the look of moderate to severe frown lines between the eyebrows.
IMPORTANT SAFETY INFORMATION for SkinPen®
SkinPen Precision™ and SkinPen Precision Elite™ are microneedling devices and accessories intended for adults aged 22 years and older to improve the appearance of facial acne scars for all Fitzpatrick skin types and wrinkles of the neck for Fitzpatrick skin types II–IV.
This treatment is not for everyone. Common post-treatment responses include temporary redness, tenderness, itchiness, dryness and peeling. Talk to your provider to learn more about whether SkinPen is right for you.
SOURCE Revance
Share this article